Company Revenue Reports

The company saw a slight decline in 4Q20 due to a repurchase of inventory from a stocking distributor, but expects growth above 30% in 2021.

The company grew +9% in 2020 despite the pandemic, buoyed by reimbursement wins and an innovative approach to drive surgeon adoption.

The company emerged from 2020 still on track to achieve its previously stated goal of doubling revenue by 2024.

The company capped 2020 with record revenues in the fourth quarter, and expects that momentum to continue in 2021.

The company grew +28% in 2020 despite the pandemic and expects to grow another +25% in 2021 as it continues building clinical distinction.

Product revenue for the company declined almost -24% in 2020, but Conformis believes it has a "game changer" in its upcoming ASC knee.

Although the company closed 2020 with strong sales from its spine franchise, it expects continued COVID-related declines through March 2021.

The company identified the $2.6 billion cervical spine surgery segment as a key growth drive in 2021 and beyond.

Armed with expanded coverage from UnitedHealthcare, Vericel expects to growth MACI in the low- to mid- +30% range in 2021.

Record Mazor robot sales, combined with near-record imaging and navigation sales, helped MDT offset COVID-related core spine declines.